Inactive Instrument

News Santhera Pharmaceuticals Holding AG Xetra

Equities

S3F

CH0027148649

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024	Apr. 25
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	Apr. 25	MT
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	Apr. 25	AQ
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	Apr. 17	MT
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	Mar. 27	MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	Mar. 27	AQ
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	Mar. 27	CI
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	Mar. 14	AQ
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	Feb. 21	CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	Feb. 14	MT
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology	Feb. 14	AQ
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	AQ
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	CI
Swiss Equities Get a Boost from UK’s Upside GDP Surprise	Jan. 12	MT
Santhera Pharmaceuticals Obtains UK Approval for Duchenne Muscular Dystrophy Treatment	Jan. 12	MT
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom	Jan. 12	AQ
Swiss Equities Edge Down After Central Banks Buzz	Dec. 18	MT
Santhera Pharmaceuticals Wins EU Nod for Duchenne Muscular Dystrophy Drug	Dec. 18	MT
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy	Dec. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Santhera Pharmaceuticals Holding AG Xetra

Equities

S3F

CH0027148649

Summary

Filters